ArticleFrontiers in medicine2026
Identification and pathogenicity analysis of a novel intronic
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: X-linked Alport syndrome (XLAS) is a disorder of type IV collagen structure caused by pathogenic variants of the COL4A5 gene and characterized by progressive kidney disease, hearing loss, and ocular abnormalities. Although mutation screening is commonly performed for AS-associated genes, transcriptional analysis is not a standard test for patients with XLAS, and the functional consequences of splicing abnormalities caused by intronic variants are rarely studied. Methods: In this study, nine family members from a three-generation pedigree in Gansu Province, China, were investigated. We used targeted next-generation sequencing to identify genetic variants in family members, confirmed the mutation site by Sanger sequencing, and predicted the pathogenicity of the variant using bioinformatics software. The splicing effects of the mutation were analyzed using minigene testing with HEK 293T cells, and further confirmed by Results: The proband was a 5-year-old male child who presented with microhematuria at the age of 4.5 years. Four relatives in this pedigree had a family history of kidney disease, all presenting with microhematuria with or without proteinuria. The proband's elder brother and maternal uncle had progressed to kidney failure. Immunofluorescence staining of the proband's epidermal basement membrane showed negative expression of the α5 chain. A novel splice variant (c.1587+4A>G) was identified in intron 23 of COL4A5 among the affected family members. Sanger sequencing confirmed that this variant co-segregated with the disease phenotype. In silico analysis predicted that this variant may cause abnormal splicing. Transcript analysis of the proband's skin tissue and minigene assay demonstrated that the variant causes abnormal mRNA splicing and exon 23 skipping, leading to a frameshift, premature termination codon, and predicted nonsense-mediated mRNA decay. Discussion: The study identified a novel intronic variant (c.1587+4A>G) in the COL4A5 gene in a Chinese family with XLAS, and functional experiments verified that this variant induces aberrant splicing. This study highlights the importance of transcript analysis for intronic variants and further expands the mutational spectrum of COL4A5 in XLAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.